leyu.ÀÖÓã(¼¯ÍÅ)ÖÇÄܿƼ¼¹É·ÝÓÐÏÞ¹«Ë¾ÍøÕ¾

    È«¹ú·þÎñ×ÉѯÈÈÏß:

    15000569291

    µ±Ç°Î»ÖãºÊ×Ò³  >  ²úÆ·ÖÐÐÄ  >  ÉúÃü¿ÆÑ§  >  Éú»¯ÊÔ¼Á  >  KE1084ÈËÔ´Ñõ»¯µÍÃܶÈÖ¬µ°°×

    ÈËÔ´Ñõ»¯µÍÃܶÈÖ¬µ°°×
    ¼òÒªÃèÊö£º

    LDLÊÇÓɼ«µÍÃܶÈÖ¬µ°°×£¨VLDL£©×ª±ä¶øÀ´£¬Ö÷Òª¹¦ÄÜÊǰѵ¨-¹Ì´¼ÔËÊ䵽ȫÉí¸÷´¦Ï¸°û£¬ÔËÊäµ½¸ÎÔàºÏ³Éµ¨ËᣬÆä¿ÉÓÃÓÚÑо¿ÊÜÌå½éµ¼µÄÄÚÍÌ×÷Óùý³Ì£¬ÓÈÆäÊÇÔÚ¶¯ÂöÖàÑùÓ²»¯µÈ¼²²¡ÖУ¬ÆäѪ½¬À´Ô´µÄLDL¿ÉÓÃÓÚÑо¿LDLÔÚ¹¦ÄܺʹúлÖеÄÑõ»¯×÷Óá£

    • ²úÆ·ÐͺţºKE1084
    • ²Î¿¼¼Û¸ñ£º1000
    • ¸üÐÂʱ¼ä£º2026-06-02
    • ·Ã  ÎÊ  Á¿£º291

    Ïêϸ½éÉÜ

    LDLÊÇÓɼ«µÍÃܶÈÖ¬µ°°×£¨VLDL£©×ª±ä¶øÀ´£¬Ö÷Òª¹¦ÄÜÊǰѵ¨-¹Ì´¼ÔËÊ䵽ȫÉí¸÷´¦Ï¸°û£¬ÔËÊäµ½¸ÎÔàºÏ³Éµ¨ËᣬÆä¿ÉÓÃÓÚÑо¿ÊÜÌå½éµ¼µÄÄÚÍÌ×÷Óùý³Ì£¬ÓÈÆäÊÇÔÚ¶¯ÂöÖàÑùÓ²»¯µÈ¼²²¡ÖУ¬ÆäѪ½¬À´Ô´µÄLDL¿ÉÓÃÓÚÑо¿LDLÔÚ¹¦ÄܺʹúлÖеÄÑõ»¯×÷Óá£

    Human Ox-LDL (Human Oxidized Low Density Lipoprotein) ÈËÔ´Ñõ»¯µÍÃܶÈÖ¬µ°°×ÊÇÐÞÊÎLDLÖеÄÒ»Àà¡£ÐÞÊεÄLDL³ý°üÀ¨Ñõ»¯ÐÞÊεÄLDLÍ⣬»¹°üÀ¨ÒÒõ£»¯LDL¼°±û¶þÈ©£¨MDA£©¡¢4-ôÇÏ©Ëᣨ4-HNE£©Ö±½Ó½áºÏµÄLDL£¬ÕâЩδ¾­Ñõ»¯ÐÞÊζø½ö¾­Ò»°ã»¯Ñ§ÐÞÊεÄLDL³ÆÎªÑÜ»¯µÄLDL¡£²»Í¬ÓÚÑÜ»¯µÄLDL£¬Ox-LDL µÄÉúÀíѧ¶ÀÌØÐÔ±íÏÖÔÚ£º1£©ÔÚϸ°ûÉúÀí¹¦ÄÜÓ°ÏìÉÏ£¬Ox-LDL¿ÉÓÕ·¢Ï¸°û¶¾ÐÔ×÷Óã¬Ó°Ï컨ÉúËÄÏ©ËáµÄ´úл£¬ÒÖÖÆµ¨-¹Ì´¼õ¥»¯×÷Óõȣ¬µ«ÑÜ»¯µÄLDLÎÞÉÏÊöЧӦ£»2£©Ox-LDLÏûºÄLDLÄÚÔ´ÐÔ¿¹Ñõ»¯ÎïÖÊ£¬Ê¹LDLÉϵÄάÉú-ËØ-Eº¬Á¿Ï½µ£¬¶øMDA-LDLÎÞÉÏÊöЧӦ£»3£©Ñõ»¯ÐÞÊÎÉæ¼°Ö¬ÖʹýÑõ»¯·´Ó¦£¬LDLÖеÄPUFAs±»Ñõ»¯¡£MDA¶ÔLDLÐÞÊΣ¬ÊÇÖ±½ÓºÍApoB-100½áºÏ³ÉÏ£·òÊϼ֬ÖʹýÑõ»¯·´Ó¦Çá΢£»4£©Ñõ»¯LDLÔÚÑõ»¯³Ì¶ÈµÍʱ£¬ApoB½µ½â£»ÔÚÑõ»¯³Ì¶È¸ßʱ£¬ApoBÓÖ¿É·¢ÉúÔپۺϡ£MDA¶ÔLDLµÄÐÞÊΣ¬ApoBÎÞ½µ½â¡¢¾ÛºÏ·´Ó¦·¢Éú£»5£©Ox-LDL ²úÉúµÄÓ«¹â·å²¨³¤Îª430nm£¬¶øMDA -LDLµÄÓ«¹â·å²¨³¤Îª460nm¡£Ox-LDL²»¾­LDLÊÜÌå´úл£¬ÓÉÇåµÀ·òÊÜÌåʶ±ð¡¢½áºÏ¡¢ÄÚÍÌÒûÈëϸ°û²¢É¥Ê§Õý³£µÄµ¨-¹Ì´¼´úл;¾¶£¬ÒýÆðϸ°ûÄÚÖ¬ÖʳÁ»ý£¬ÅÝÄ­Ñù±ä¡£

    LDLÑõ»¯ÐÞÊεķ½Ê½ÓкܶàÖÖ£¬³£¼ûµÄÓУº1£©Ï¸°û½éµ¼µÄLDLÑõ»¯ÐÞÊΣ¬ÓÖ³ÆÎªÉúÎïÑõ»¯ÐÞÊεÄLDL¡£ÈçÄÚÆ¤Ï¸°û£¬¾ÞÊÉϸ°û£¬µ¥ºËϸ°û¶¼¾ßÓд˹¦ÄÜ£»2£©¹ý¶È½ðÊôÀë×ӽ鵼µÄLDLÑõ»¯ÐÞÊΣ¬ÈçCa2+£¬Fe2+µÈ£»»¹ÓÐÆäËûÐÎʽµÄÑõ»¯ÐÞÊΣ¬°üÀ¨ÎïÀí·½·¨Èç×ÏÍâÏߣ¬»ò¹ýÑõ»¯Îïø´ß»¯¡£

    ±¾²úÆ·ÊÇÓɹý¶ÈÍ­Àë×ӽ鵼ÈËѪ½¬À´Ô´µÄLDL½øÐеÄÑõ»¯ÐÞÊΣ¬ÎÞ¾ú°ü×°£¬¿ÉÒÔÖ±½ÓÏ¡ÊÍʹÓᣱ¾Ox-LDL¹ã·ºÓÃÓÚÖ¬ÖÊ´úлµÄÑо¿¡£ÁíÍâÎÒÃÇ»¹ÌṩHigh Ox-LDL¿É²úÉúÃ÷ÏÔµÄÑõ»¯Ó¦¼¤£¬Äܹ»ÓÃÀ´ÓÕµ¼Ï¸°ûµòÍö£¬²¢½¨Á¢Ï¸°ûËðÉËÄ£ÐÍ¡£³ýÌṩOx-LDL£¬ÎÒÃÇ»¹ÌṩÈËÔ´ÒÒõ£»¯LDL£¨Ac-LDL£©£¬ÒÔ¼°Ó«¹â±ê¼ÇµÄLDL¡£

    ²úÆ·ÊôÐÔ
    ´¿¶È£º£¾95%
    Ũ¶È£º0.8-4.0 mg/ml ´Ë¿î²úƷΪ2.3mg/ml(Protein)

    ÄÚ¶¾ËØ£º< 0.5EU/mg(Protein)
    Íâ¹Û£ºÈé×´ÒºÌå
    »º³åÒº×é·Ö£º0.02 mM EDTA in PBS, pH 7.4

    Ñõ»¯³Ì¶È£ºTBARS¼ì²â£¨¸ù¾ÝMDAµÄº¬Á¿·´Ó³LDLµÄÑõ»¯³Ì¶È£©

    TBARS Îì¶þÈ©¶¨Á¿·ÖÎö¼ì²âÑõ»¯³Ì¶È>18 nmoles MDA/mg µ°°×¡£

    Æðʼ LDL <0.5nmoles MDA/mg µ°°×

    Ox-LDL >10 nmoles MDA/mg µ°°×

    ¶¯ÎïˮƽÄÚ¶¾Ëؼì²â£º <0.5 EU/mg µ°°×

    ÉúÎï»îÐÔ¼ì²â£ºÍ¨¹ýÌØ¶¨Ï¸°ûϵ SR-A ÊÜÌå½éµ¼µÄÄÚÍÌÑéÖ¤ÆäÄÚÍÌ»îÐÔ£¬ÓëÌìÈ»µÍÃܶÈÖ¬µ°°×Ïà±È£¬Ñõ»¯µÄµÍÃܶÈÖ¬µ°°×£¬¿ÉÌØÒìÐԵı»±í´ï SR-A ÊÜÌåµÄ¸÷Ààϸ°ûÄÚÍÌ¡£

    Dil labeled Ox-LDL and native LDL were added into 293T cell medium for internalization, after 12 hr internalization, cells were detected by FACS. 293T cells were transfected by GFP tagged SR-A1.

    ÔËÊäÓë±£´æ·½·¨£º±ù´üÔËÊä¡£4¡æ±£´æ£¬½¨Òé±Ü¹â£¬6ÖÜÎȶ¨¡£Ç§Íò²»¿É¶³´æ£¡£¡

    ×¢ÒâÊÂÏî
    1£©±¾Æ·µÄÏ¡Ê͹¤×÷Òº¼«²»Îȶ¨£¬½¨Òé¼´Åä¼´Óã»
    2£©³¤ÆÚÖü´æ¿ÉÄÜ»áÓгÁµíÎö³ö£¬ÊôÓÚÕý³£ÏÖÏ󣬵ÍËÙ£¨1000g£©ÀëÐÄ2-3 minÈ¥³ý³Áµí¼´¿ÉʹÓã»
    3£©ÎªÁËÄúµÄ°²È«ºÍ½¡¿µ£¬Ç봩ʵÑé·þ²¢´÷Ò»´ÎÐÔÊÖÌײÙ×÷¡£


    ²úÆ·×Éѯ

    ÁôÑÔ¿ò

    • ²úÆ·£º

    • ÄúµÄµ¥Î»£º

    • ÄúµÄÐÕÃû£º

    • ÁªÏµµç»°£º

    • ³£ÓÃÓÊÏ䣺

    • Ê¡·Ý£º

    • ÏêϸµØÖ·£º

    • ²¹³ä˵Ã÷£º

    • ÑéÖ¤Â룺

      ÇëÊäÈë¼ÆËã½á¹û£¨Ìîд°¢À­²®Êý×Ö£©£¬È磺Èý¼ÓËÄ=7

    È«¹úͳһ·þÎñµç»°

    18721768236£»13122976992

    µç×ÓÓÊÏ䣺zhanlingrui@163.com

    ¹«Ë¾µØÖ·£ºÉϺ£ÊÐãÉÐÐÇø¾°ÁªÂ·439ºÅ5ºÅÂ¥515

    ɨÂë¼Ó΢ÐÅ

    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿